TG Therapeutics Inc (TGTX)

Working capital turnover

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	US$ in thousands	324,397	221,047	2,785	6,689	152
Total current assets	US$ in thousands	566,359	317,943	168,274	330,965	611,740
Total current liabilities	US$ in thousands	90,679	53,720	53,201	65,384	87,554
Working capital turnover		0.68	0.84	0.02	0.03	0.00

December 31, 2024 calculation

Working capital turnover = Revenue ÷ (Total current assets – Total current liabilities)
= $324,397K ÷ ($566,359K – $90,679K)
= 0.68

The working capital turnover ratio measures a company's ability to efficiently utilize its working capital to generate sales. A higher ratio indicates that the company is effectively using its working capital to support its operations and generate revenue.

Based on the data provided for TG Therapeutics Inc:
- In December 31, 2020, the working capital turnover was 0.00, indicating that the company did not effectively utilize its working capital to generate sales during that period.
- In December 31, 2021, the ratio improved to 0.03, showing a slight increase in the efficiency of working capital utilization.
- In December 31, 2022, the ratio decreased to 0.02, suggesting a temporary decline in the efficiency of working capital turnover.
- In December 31, 2023, there was a significant improvement in the ratio to 0.84, indicating a substantial increase in the efficiency of working capital utilization.
- In December 31, 2024, the ratio decreased slightly to 0.68, but still remained at a relatively high level compared to previous years.

Overall, the working capital turnover for TG Therapeutics Inc has shown fluctuations over the years, with significant improvements in some periods and minor declines in others. It is essential for the company to maintain a balance between efficient working capital management and sales generation to ensure sustainable growth and profitability.